Navigation Links
Chronic Kidney Disease: Reducing Risks of Progression-- Prismic Pharmaceuticals Secures Exclusive Licensing Rights
Date:6/13/2013

SCOTTSDALE, Ariz., June 13, 2013 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based pharmaceutical company, today announced that it has secured exclusive licensing rights to Palmitoylethanolamide (PEA), including the micronized and ultra-micronized forms, a novel non-steroidal, kidney-friendly anti-inflammatory and anti-fibrotic agent with a well-documented safety profile in humans.

Commenting on securing the rights to this important new agent, Prismic's Chief Medical Officer, Dr, Teo Forcht Dagi, said, "Inflammation and oxidative stress play a key role in the induction and the progression of Chronic Kidney Disease (CKD).  This is particularly so in diabetic patients, and it is most likely that inflammation is a major factor in the pathogenesis and progression of diabetic nephropathy. In addition, an increase in inflammatory cytokine levels in diabetes may increase oxidative stress as renal injury becomes more pronounced, thereby establishing a vicious cycle. Prismic, therefore, plans to undertake further clinical development with PEA to prove the concept that this molecule is capable of interrupting this cycle without adversely affecting renal function."

Dr. Forcht Dagi also went on to point out that it is believed that "by reducing low grade chronic inflammation and by inhibiting oxidative stress, PEA may reduce risk factors associated with the  progression of Chronic Kidney Disease (CKD) and have the potential to offer significant benefit to patients with CKD at early and, quite possibly, even at late stages of the disease."

Prismic Pharmaceuticals has secured worldwide licensing rights (with the exception of Italy and Spain) for PEA from the Epitech Group SRL, and has rights in all regulatory categories for CKD.  Epitech's CEO, Raffaella della Valle, commented that "PEA has been explored in man in various clinical trials in a variety of pain states, for inflammatory and pain syndromes, and has an extremely well-documented safety profile."  She also stated that "Epitech has a very robust portfolio of issued patents covering PEA in all the major countries of the world. We are, therefore, confident that with Prismic's strong management team and worldwide partnering connections, Prismic will be able to maximize the commercial opportunities for PEA, as well as undertaking any additional clinical development work to further develop the product in other indication areas."

About Prismic Pharmaceuticals, Inc.
Prismic Pharmaceuticals, Inc., is a privately held pharmaceutical company focused on the development and marketing of prescription medical foods for the clinical dietary management of the metabolic processes associated with many of the disorders associated with the aging population, particularly where inflammation is involved.  The company is based in Scottsdale, Arizona, and was founded in 2011. Contact 480.422.1810 or visit www.PrismicPharma.com.

About Epitech group SRL.
Epitech Group SRL is a pharmaceutical company, headquartered in Padova, Italy, with a strong commitment to R & D in the pharmacology of biological modulation.  It has developed and markets a range of products in Italy and Spain directly and through commercial partners. www.Epitech.it

INFORMATION CONTACT
Teo Forcht Dagi, MD, MPH, DMedSc
Tel: 480.320.1003


'/>"/>
SOURCE Prismic Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
2. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
3. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
4. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
5. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
6. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
7. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
8. Remote Patient Monitoring Devices Market to 2017 - Chronic Disease Prevalence and Government Curbs on Hospital Spending to Drive the Market
9. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
10. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
11. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):